Pharmacokinetics of Two Randomized Trials Evaluating the Safety and Efficacy of Indinavir, Saquinavir and Lopinavir in Combination with Low-Dose Ritonavir: The MaxCmin1 and 2 Trials

Simple item page
dc.contributor.authorJustesen, Ulrik S
dc.contributor.authorFox, Zoe
dc.contributor.authorPedersen, Court
dc.contributor.authorCahn, Pedro
dc.contributor.authorGerstoft, Jan
dc.contributor.authorClumeck, Nathan
dc.contributor.authorLosso, Marcello
dc.contributor.authorPeters, Barry
dc.contributor.authorObel, Niels
dc.contributor.authorCastagna, Antonella
dc.contributor.authorDragsted, Ulrik B
dc.contributor.authorLundgren, Jens D
dc.contributor.authorn behalf of the MaxCmin1 and 2 trial groups
dc.date.accessioned2024-05-23T23:49:04Z
dc.date.available2024-05-23T23:49:04Z
dc.date.issued2007-08-10
dc.descriptionFil: Cahn P. Fundación Huésped, Buenos Aires; Argentinaes_ES
dc.description.abstractAbstract: Our objective was to identify possible differences in protease inhibitor plasma concentrations between and within three protease inhibitor regimens (indinavir, saquinavir and lopinavir all in combination with low-dose ritonavir) and to relate these differences to safety and efficacy. Data originated from pre-defined pharmacokinetic substudies within two randomized 48-week trials evaluating the safety and efficacy of three protease inhibitor regimens. At weeks 4 and 48, plasma was collected and minimum drug plasma concentrations, Cmin, were obtained. Out of 656 randomized patients, 283 patients had available Cmin at week 4. Indinavir, saquinavir and lopinavir Cmin were high when combined with low-dose ritonavir. No significant difference in the proportion of patients experiencing treatment failure could be found according to the Cmin within any treatment arm. A saquinavir Cmin > 2000 ng/ml was associated with an increased risk of gastrointestinal grade 3 or 4 adverse events and higher total cholesterol. Overall, there were no changes in Cmin from week 4 to week 48 in patients who remained on therapy. No association between treatment failure and the Cmin could be demonstrated. Associations between high Cmin and toxicity were identified in the saquinavir arm; therefore, dose reductions may be appropriate in certain patients with Cmin several times above the minimum effective concentration.es_ES
dc.formatapplication/pdfes_ES
dc.identifier.doihttps://doi.org/10.1111/j.1742-7843.2007.00117.x
dc.identifier.urihttps://repositorio.huesped.org.ar/handle/123456789/1304
dc.languageENGes_ES
dc.provenancePublishedes_ES
dc.relation.ispartofseriesBasic & Clinical Pharmacology & Toxicology;2007 Nov;101(5);339-44
dc.rightsopenAccesses_ES
dc.subjectPharmacokineticses_ES
dc.subjectIndinavires_ES
dc.subjectSaquinavires_ES
dc.subjectLopinavires_ES
dc.titlePharmacokinetics of Two Randomized Trials Evaluating the Safety and Efficacy of Indinavir, Saquinavir and Lopinavir in Combination with Low-Dose Ritonavir: The MaxCmin1 and 2 Trialses_ES
dc.typeArticuloes_ES

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
10.1111j.1742-7843.2007.00117.x.pdf
Size:
97.94 KB
Format:
Adobe Portable Document Format
Description:
10.1111/j.1742-7843.2007.00117.x_eng
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Plain Text
Description:
Download

Collections

Articulos científicos